Don't miss our poster presentation at ASCO 2025. Colorectal cancer (CRC) is the third most common cancer worldwide and a leading cause of cancer mortality, with ~33% of patients developing metastases and a poor 5-year survival rate of ~15%. While surgical resection...

Join us at DDW25 to explore how ClearNote Health is harnessing the power of the epigenome to drive early pancreatic cancer detection and transform patient outcomes. 📍 Visit us at booth #5525 to learn more about the @Avantect Pancreatic Cancer Test - a simple,...

We will be attending the AACR Annual Meeting, April 25-30, 2025, taking place at the McCormick Place Convention Center, Chicago, Illinois. Don't miss our poster presentations: Title: 5hmC-sequencing of matched cfDNA and tissue from men with mCRPC is concordant and...

ClearNote Health will be attending the 2025 ACMG Annual Clinical Genetics Meeting, March 18-22, Los Angeles. Don't miss our poster presentation: Presenter: Shimul Chowdhury, PhD, FACMG, CGMB, Vice President of Laboratory Operations Submission ID: 625881...

ClearNote Health will be at TRI-CON 2025. Meet us at booth 3 and learn more about ClearNote Health's Virtuoso Epigenomics Platform. Virtuoso leverages 5hmC epigenomic profiling to uncover active cancer biology patterns from cfDNA in plasma, empowering more efficient...

ClearNote Health's VP Translational Research & Head of Biopharma Development, Gulfem D. Guler, is attending the American Society of Clinical Oncology (ASCO) GU25 Symposium, February 13-15, San Francisco. Connect with Gulfem to learn more about ClearNote Health's...

ClearNote presented a poster entitled: “Cell-type specific signatures in plasma cell-free DNA 5-hydroxymethylome enables cancer detection and response monitoring in non-small cell lung cancer patients undergoing anti-PD-1 treatment.”

ClearNote presented a poster entitled: “Cancer-induced epigenomic changes in circulating immune cells enable breast, colorectal and lung cancer detection.”

ClearNote attended with booth (#6).

ClearNote Health presented findings from a clinico-economic analysis of its Avantect Pancreatic Test in a poster entitled “Cell-Free DNA Epigenomic-based Test is Predicted to Be Cost Effective to Manage New-Onset Type 2 Diabetes Patients for Risk of Pancreatic Cancer”...